Articles: PDF OnlyThe Role of Parenteral Antipsychotics in Clinical Practice—Part IIWinans, Elizabeth A. PharmD, BCPP; Janicak, Philip G. MD Author Information CME article by Elizabeth A. Winans, PharmD, BCPP, Clinical Assistant Professor, University of Illinois at Chicago College of Pharmacy and Department of Psychiatry; and Philip G. Janicak, MD, Professor of Psychiatry, Medical Director, Psychiatric Clinical Research Center, Department of Psychiatry, University of Illinois at Chicago Dr. Winans has disclosed that she is on the speakers' bureau of Bristol Myers Squibb. Dr. Janicak has disclosed that he receives grant/research support from the NIH, Genentech, Bristol Myers Squibb, and Janssen; is a consultant for Janssen, Pfizer, Sepracor, and Novartis; and is on the speakers' bureau of Abbott Labs, Janssen, Pfizer, Bristol Myers Squibb, Novartis, Wyeth-Ayerst, Forest, and Eli Lilly. The authors also have disclosed that they have included investigational information for the intramuscular (IM) formulations of ziprasidone, olanzapine, and risperidone. All three drugs are undergoing clinical development in the United States. The IM formulation of clozapine is not marketed in the United States, and to their knowledge is not undergoing clinical development in the United States. International Drug Therapy Newsletter: April 2002 - Volume 37 - Issue 4 - p 25-32 Buy Abstract Learning Objectives: After reading this article, the practitioner should be better able to: List the atypical parenteral agents currently under investigation. Discuss the potential clinical use of atypical parenteral formulations. Compare and contrast the most common adverse effects of the traditional and atypical antipsychotic parenteral formulations. © 2002 Lippincott Williams & Wilkins, Inc.